Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of MV140

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women who gave their informed consent.~* Age between 18 and 75 years.~* Must be able to meet the dosage regimen.~* Subjects who had had at least 5 episodes of cystitis in the last 12 months.~* Subjects who had not responded to hygienic-sanitary measures and / or suppressive treatment and / or postcoital prophylaxis.~* Subjects who were free of urinary tract infections at the time of inclusion in the study.~Exclusion Criteria:~* Had not given their informed consent.~* Age was not within the established age range.~* Could not offer cooperation and/or had severe psychiatric disorders.~* Presented a pathologic post-micturition residue.~* Presented moderate to severe incontinence.~* Presented genital tumours.~* Presented Urinary tract tumours.~* Presented lithiasis.~* Presented alterations in the immune system.~* Presented complicated UTIs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MV140 I (Type: EXPERIMENTAL): The subjects will receive daily dose of MV140 during 6 months
- MV140 II (Type: EXPERIMENTAL): The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
- Placebo (Type: PLACEBO_COMPARATOR): The subjects will receive daily dose of placebo during 6 month

Based on this trial design, predict the completion outcome and termination type (if applicable).